CD47 monoclonal antibody

PreclinicalSmall molecule

TThe First Affiliated Hospital of Soochow University

CD47 monoclonal antibody is one of 3 small molecule programs targeting Clinical Efficacy and Safety. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Clinical Efficacy and SafetyUnknown status

Clinical Efficacy and SafetyPreclinical

Unknown status

Competition

Competitive Landscape

2 competitors in Clinical Efficacy and Safety

#DrugCompanyPhaseTrials

Analgesic

CCeren Melahat Donmezer

Preclinical

1 2

CD47 monoclonal antibody

TThe First Affiliated Hospital of Soochow University

Preclinical

1 3

Compound Methyl Salicylate Liniment

PPeking University People's Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Clinical Efficacy and Safety1 trial

Clinical Efficacy and Safety of CD47 Monoclonal Antibody Combined With Azacitidine in the Treatment of Recurrent AML After Transplantation

Unknown status·TThe First Affiliated Hospital of Soochow University·N/A·NCT05266274·69 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CD47 monoclonal antibody. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD47 monoclonal antibody compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD47 monoclonal antibody. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital of Soochow University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe First Affiliated Hospital of Soochow University

CD47 monoclonal antibody

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Clinical Efficacy and Safety1 trial

References

Drug Info

Quick Facts

Related News